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Introduction 
B-cell chronic lymphocytic leukemia (B-CLL) is the
most frequent malignancy in Western countries [1].
The immunsuppression commonly accompanies other
symptoms of disease. This phenomenon might be
explained by i) increased level of immunosuppresive
cytokine IL-10 [2], ii) increased frequencies of T reg-
ulatory cells in B-CLL patients [3,4] iii) decresed func-
tion of DC and T cells [5] and iv) hypogammaglobu-
linemia [6]. However some other mechanisms might
be also involved in the escape of CLL cells from
immunosurveillance. The expression of HLA-G was
reported in certain malignancies and its role in escap-
ing from immunosurveillance in cancers was proposed
since HLA-G is a nonconventional HLA class I mole-
cule expressed on trophoblast cells and therefore pro-
tecting fetus from immunorecognition during pregnan-
cy [7]. Nuckel et al. [8] reported on the expression of
HLA-G on CLL leukemic cells. Moreover it was con-
cluded that HLA-G might constitute a novel prognos-
tic factor superior to well established prognostic fac-
tors for patients with B-CLL such as Zeta-chain asso-
ciated protein of 70kDa (ZAP-70) and CD38. In con-
trast Polakova et al. [9] in their comprehensive study
on HLA-G in hematological malignancies described
no expression of this protein on B-CLL cells. Recent-
ly, we compared two different staining techniques for
the assessment of HLA-G molecule on protein level in
B-CLL [10]. Both direct staining as well as non-direct
staining were positive for CLL patients however it
seemed that primary staining with pure anti-HLA-G
antibody followed by staining with secondary anti-
body was more sensitive. To characterize the expres-
sion of HLA-G in B-CLL, in the current study the
HLA-G protein was measured using flow cytometry
analysis and HLA-G expression was confirmed on
messenger RNA level by real-time RT-PCR.
Material and methods
Patients. Twenty patients with untreated B-CLL, 13 males and 7
females (mean age 65.5 years; range 51-74), were included in this
study. Sixteen patients were classified in early stage of disease
(stage 0 to 2 according to Rai classification) and four were classi-
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fied advanced (stage 3 and 4). The expression of prognostic factors
ZAP-70 and CD38 was assessed as described in details [11].
Peripheral blood mononuclear cells (PBMC) were isolated by
Ficoll (Biochrom, Germany) density gradient centrifugation. The
viability of obtained PBMC was always >95%, as determined by
trypan blue exclusion (Sigma-Aldrich, Germany). The viable cells
were quantified in a Neubauer chamber (Zeiss, Germany) and
stored for RNA preparation at – 192°C in liquid nitrogen.
Flow cytometric analysis of cell surface antigens. The following
FITC-, PE- and PerCP-conjugated monoclonal antibodies (moAb)
were used for three colour flow cytometry analysis: anti-CD5PE
(BD Biosciences,USA), anti-CD19 PerCP (BD Biosciences,USA).
For moAb anti-HLA-G pure, clone MEM-G/9 (BD Pharmigen,
USA) 106 cells were incubated for 20 min. at 4°C, thereafter washed
and stained with secondary goat anti-mouse antibody conjugated
with FITC (Dako, Denmark). In the following secondary staining
cells were washed twice and stained with CD5 and CD19 for addi-
tional 15 minutes. Relevant isotype mouse controls were used.
Before flow cytometric analysis, FACScalibur flow cytometer (BD
Biosciences, USA) was calibrated. After immunofluorescence stain-
ing, cells were washed twice and 20.000 events were acquired and
analysed using CellQuest software (BD Biosciences, USA).
mRNA preparation and reverse transcription. For the isolation
of mRNA from PBMC, the µMACS mRNA Isolation Kit (Miltenyi
Biotec, Bergisch Gladbach, Germany) was used according to the
manufacturer's instructions. Briefly, after cell lysis, RNA was incu-
bated with 50 µl Oligo (dT) Micro Beads (Miltenyi Biotec, Ber-
gisch Gladbach, Germany) then isolated in the magnetic field
through the MACS column Type µ (Miltenyi Biotec). After wash-
ing isolated mRNA was released from the column by pre-heated
Elution Buffer (Miltenyi Biotec). The quality and quantity of the
isolated mRNA was assessed using an Eppendorf BioPhotometer
(Eppendorf, Hamburg, Germany). Fifty ng of mRNA was reverse
transcribed into 20 µl of cDNA using a 1st Strand cDNA Synthe-
sis Kit for RT-PCR (AMV) (Roche Diagnostics, Mannheim, Ger-
many). For each RT-PCR 1 µl of the cDNA preparation was used.
Quantitative "real time" reverse transcriptase polymerase
chain reaction (qRT-PCR). For the quantitative measurement of
the mRNA expression of HLA-G real-time RT-PCR was per-
formed using the Light Cycler SYBR Green I technology accord-
ing to the manufacturer's protocol (Roche Diagnostics). The
TATA-Box binding protein (TBP) was used as a house-keeping
gene. An initial denaturation step at 95°C for 10 min was fol-
lowed by 40 cycles of 10 s at 95°C, 15 s at 62°C, 20 s at 72°C for
the TBP. Real-time PCR for HLA-G was carried out with the
G.948 forward primer located in exon 5 (5’-
CTGGTTGTCCTTGCAGCTGTAG-3') and the G.1002 reverse
primer located in both sides of exon 5 and exon 6 (5’-
CCTTTTCAATCTGAGCTCTTCTTTCT-3'). For the gene HLA-
G an initial denaturation step at 95°C for 10 min was followed by
45 cycles of 10 s at 95°C, 10 s at 62°C, 12 s at 72°C. 0.1 µl of
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Table 1. Expression of HLA-G in patients with B-CLL (NA-not available).
cDNA was used per qRT-PCR. To quantify the mRNA expression
of HLA-G, a conventional PCR for HLA-G from placenta was
performed and the amount of product cDNA was measured by
photometry using an Eppendorf BioPhotometer (Eppendorf). A
serial dilution of cDNA was subjected to PCR to obtain standard
curves. The amount obtained by quantitative measurement of
mRNA in attogram (ag) for HLA-G and TBP was calculated into
copy numbers and normalized against the house keeping gene
TBP, of which hitherto no retro-pseudogenes are known. 
Statistical analysis. To compare HLA-G expression by groups of
CLL patients, the non-parametric U Mann-Whitney test was used.
Results lower than 0.01 were considered to be significant. Statisti-
cal analyses were performed using STATISTICA 5.1 (StatSoft,
StatSoft Polska, Poland). 
Results
The expression of HLA-G was detected in all CLL
patients both on messenger RNA and protein level. 
Using pure moAb, clone MEM-G/9 followed by
secondary staining with goat antimouse moAb conju-
gated with fluorochrome, the median percentage of
HLA-G expression in CLL cells was 7.15 (min-max:
0.3 – 60.3). Examples of flow cytometry analysis are
shown in Fig. 1. No correlation with stage was detect-
ed. The expression of HLA-G did not differ signifi-
cantly in patients CD38(+) and CD38(-) neither in
FACS analysis nor in "real time" RT-PCR experi-
ments. No different expression of HLA-G was detect-
ed in patients ZAP-70(+) and ZAP-70(-) neither in
FACS analysis nor in "real time" RT-PCR experi-
ments. No correlation between mRNA level of HLA-G
and HLA-G expression on protein level was found
(r2=-0.28, ns). Results are summarized in Table 1.
Discussion
HLA-G is a non-classical MHC molecule expressed in
immune-priviledged areas where it plays an important
role in the tolerance to fetal antigens. From 1998 when
Paul et al. [12] for the first time described the expres-
sion of HLA-G in solid tumors, its re-expression dur-
ing tumorigenesis is linked to suppress tumor recogni-
tion by immune system. Enhanced expression of HLA-
G was found in several malignancies suggesting that
HLA-G is involved in the escape of tumor cells from
the immunosurveillance [7]. In this study the expres-
sion of HLA-G on both messenger and protein level
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Fig. 1. Assessment of HLA-G expression in chronic lymphocytic leukemia (CLL) cells using flow cytometry. PBMC were analyzed using
three color flow cytometry analysis. CLL cells were gated as double positive cells for CD5 and CD19 (A for patient 3 and D for patient
12) and percentage of cell positive for HLA-G were noted (C and F for patients 3 and 12, respectively) with regard to isotype controls
(B and E).
was observed. Similar results were shown by Nuckel
et al. [8] who found the expression of HLA-G in B-
CLL on protein level and showed its prognostic
properities for patients with B-CLL. In contrast
Polakova et al. [9] found no expression of HLA-G on
protein level using complex panel of monoclonal anti-
bodies against HLA-G. On the other hand Amiot et al.
[12] in comprehensive study on HLA-G expression in
lymphoproliferative disorders showed the increased
mRNA level of HLA-G. Interestingly enhanced
expression of HLA-G mostly resulted in the increased
serum levels of soluble HLA-G but hardly with
increased expression as HLA molecule on cell surface.
Amiot et al. [13] reported on the increased levels of
soluble HLA-G (sHLA-G) in B-CLL patients. Aug-
mented concentrations of sHLA-G might favor the
progression of cancer by the inhibition of the function
of T as well as NK cells [14]. It was suggested that
HLA-G inhibits T cells and DC acts via ILT-2 (CD85j)
and ILT4 (CD85d) [15,16]. CLL cells express the
HLA-G receptor ILT-2 [17]. The interaction between
HLA-G tetramers with ILT-4 receptor on DC resulted
in the reduced expression of HLA-DR [18]. Rebmann
et al. [19] speculated whether the reduced expression
of HLA-DR on B-CLL cells is attributed to the inter-
action of sHLA-G with the ILT-2 receptor on B-CLL
cells. The discrepancy between the expression of
HLA-G on mRNA and protein level observed in this
study in CLL cells might indicate that a part of trans-
lated HLA-G is released as sHLA-G.
In the current study no correlation of HLA-G
expression neither on protein nor on messenger level
with well established prognostic factors for B-CLL
ZAP-70 and CD38 was detected. Nuckel et al. [8] also
didn't find any correlation between HLA-G and ZAP-
70 and CD38, however they found that the increased
levels of HLA-G (cut-off 23%) resulted in a signifi-
cantly shorter time to progression suggesting that
HLA-G might serve as a surrogate prognostic factor in
CLL. In our study we could not confirm this relation-
ship, possibly due to a limited number of patients.
In summary, our study revealed the expression of
HLA-G in B-CLL on protein level and confirmed
using real-time RT-PCR. The expression of HLA-G in
B-CLL suggests that this molecule might represent an
additional mechanism of tumor escape from the
immunosurveillance. 
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